Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

• Published in: Hepatology (Baltimore, Md.) Vol. 68; no. 1; pp. 349 - 360
• Main Authors: Younossi, Zobair M., Loomba, Rohit, Anstee, Quentin M., Rinella, Mary E., Bugianesi, Elisabetta, Marchesini, Giulio, Neuschwander‐Tetri, Brent A., Serfaty, Lawrence, Negro, Francesco, Caldwell, Stephen H., Ratziu, Vlad, Corey, Kathleen E., Friedman, Scott L., Abdelmalek, Manal F., Harrison, Stephen A., Sanyal, Arun J., Lavine, Joel E., Mathurin, Philippe, Charlton, Michael R., Goodman, Zachary D., Chalasani, Naga P., Kowdley, Kris V., George, Jacob, Lindor, Keith
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health, Inc 01.07.2018
• Subjects: Biomarkers - blood; Biopsy; Cirrhosis; Clinical trials; Collagen - metabolism; Fatty liver; Fibrosis; Hepatology; Humans; Liver - pathology; Liver cirrhosis; Liver Cirrhosis - blood; Liver Cirrhosis - diagnostic imaging; Liver Cirrhosis - etiology; Liver Cirrhosis - pathology; Liver diseases; Non-alcoholic Fatty Liver Disease - blood; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - diagnostic imaging; Non-alcoholic Fatty Liver Disease - pathology; Steatosis
• ISSN: 0270-9139; 1527-3350; 1527-3350
• DOI: 10.1002/hep.29721

Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis, nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. The majority of NAFLD subjects do not have NASH and do not carry a significant risk for liver‐related adverse outcomes (cirrhosis and mortali...